Ultragenyx Pharmaceutical Stock
Ultragenyx Pharmaceutical Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Emil D. Kakkis
- Employees
- 1,371
- Market cap
- $1.4 B
- IPO
- 31/01/2014
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Headquartered in Novato, USA, the company was founded in 2010. Its operations span North America, Europe, and other international…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Ultragenyx Pharmaceutical stock: price history
1D
-4.2%
1W
-6.1%
1M
+12.9%
6M
-41.4%
YTD
-36.8%
1Y
-57.2%
2Y
-74.8%
5Y
-81.8%
10Y
-76.6%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~2% weaker price swings than usual
Ask the agents about Ultragenyx Pharmaceutical
Analyst assessment of Ultragenyx Pharmaceutical
PRICE TARGET LOW
US$16.00
CONSENSUS
US$25.46
MEDIAN
US$23.00
PRICE TARGET HIGH
US$39.00
0
STRONG BUY
22
BUY
11
HOLD
1
SELL
0
STRONG SELL
34
TOTAL · Buy
As of: 21/09/2026
Ultragenyx Pharmaceutical stock metrics
P/E
-2.49
P/B
-5.09
EV/EBITDA
-5.31
RETURN ON EQUITY
31.6%
NET MARGIN
-43.0%
DEBT/EQUITY
-4.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.1%
FLOAT SHARES
94,701,059
AVG. DAILY VOLUME (30D)
5,330,421
Insider transactions (SEC)
Huizenga Theodore Alan
Huizenga Theodore Alan
Horn Howard
Parschauer Karah Herdman
Horn Howard
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.2%
Forums (Reddit)
See the full forum history with Pro.
Institutional holders
Comparable stocks
Frequently asked questions about Ultragenyx Pharmaceutical stock
What does Ultragenyx Pharmaceutical do?
Ultragenyx Pharmaceutical Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Emil D. Kakkis, the company employs around 1,371 people.
The IPO was on 31/01/2014; the stock trades on NASDAQ under the ticker RARE.
What do analysts say about Ultragenyx Pharmaceutical stock?
34 analysts rate the stock, the consensus is Buy (as of 21/09/2026).
The average price target is US$25.46, ranging from US$16.00 to US$39.00, with a median of US$23.00.
This is an external assessment, not a statement by Market Jury.
When does Ultragenyx Pharmaceutical report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -2% stronger than usual.
Does Ultragenyx Pharmaceutical pay a dividend?
No, Ultragenyx Pharmaceutical currently does not pay a dividend.
Which stocks are comparable to Ultragenyx Pharmaceutical?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ultragenyx Pharmaceutical stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ultragenyx Pharmaceutical against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.